The Unexpected Gift: Finding Your Superpower in the Face of Adversity | Ricki Fairley | TEDxBoston

Quick Overview

Ricki Fairley transformed her diagnosis of aggressive, metastatic triple-negative breast cancer, which carries a 41% higher mortality rate for Black women, into her "God job" by leveraging her marketing background to launch the Touch the Black Breast Cancer Alliance and the "When We Trial" movement to increase Black participation in clinical trials and advocate for science that addresses racial differences in cancer cells.

Key Points: Ricki Fairley was diagnosed with triple-negative breast cancer, the worst type with the least treatment options and highest mortality rate, which affects Black women at three times the rate of white women. After initial treatment, her cancer metastasized with a two-year prognosis, leading her to find specialized research through the Triple Negative Breast Cancer Foundation and join a clinical trial drug protocol, resulting in survival for 13 years. Black women face a 41% higher mortality rate from breast cancer than white women, and even with good insurance or high socioeconomic status, they maintain significantly higher mortality rates, indicating a scientific disparity. Research validates that "a black breast cancer cell looks totally different than a white breast cancer cell," and historically, Black women were absent from clinical trials, meaning standard-of-care drugs were developed without them in mind. Fairley used her 30 years of marketing acumen to found the Touch the Black Breast Cancer Alliance, focusing on changing perceptions and advancing science, encapsulated by her premise: "no is never the answer. It's always how." Her research revealed doctors do not invite Black women into trials, and a significant fear exists that participants will receive a "sugar pill," leading her to launch the "When We Trial" campaign to educate the community in trusted voices. Fairley established a 24/7 nurse navigation program staffed by Black women breast cancer survivors to provide support, advice, and hugs around the science, aiming to make the clinical trial experience supportive rather than sterile.